Huizinga Robert Bindert's Form 4 filing
Aurinia Pharmaceuticals Inc. (AUPH) · filed Oct 26, 2021
- Accession no.
- 0001628280-21-020527
- Filed
- Oct 26, 2021
- Trade date
- Oct 25, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.87M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Huizinga Robert BindertCIK 0001837648 | Officer (EVP of Research) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2021 | Common Stock | MOption exerciseAcquired | +95,000 | $3.20 | +$304,000 | 195,728 | Direct | |
| Oct 25, 2021 | Common Stock | SSaleDisposed | −130,000 | $29.75 | −$3,867,500 | 65,728 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2021 | Common Stock | MOption exerciseDisposed | −95,000 | $0.00 | $0 | 3,864 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.